University of Alabama at Birmingham
Birmingham, AL, United States
Dr. Singh is a Professor of medicine and epidemiology at the University of Alabama at Birmingham, Director of the Gout Clinic at the University of Alabama Health Sciences Foundation and a staff rheumatologist at the Birmingham Veterans Affairs Medical center. Dr. Singh’s research has focused on studies of outcomes in patients with rheumatic diseases, using databases and performing interventional studies to improve outcomes in patients with rheumatic diseases. His previous studies have focused on assessing correlates and predictors of patient-reported outcomes including quality of life, pain, and function in large cohorts of patients with gout, osteoarthritis and other types of musculoskeletal diseases. His current research interests include conducting translational and clinical research in patients with gout, osteoarthritis and lupus and studies assessing patient shared decision-making.
Racial Disparities and Health Inequities in Gout Care in the U.S. and Potential Remedies
Sunday, November 12, 2023
2:30 PM – 2:45 PM PT
Disclosure(s): Other: Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web (Ongoing), Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma (Ongoing), Consultant (Ongoing), received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec (Ongoing), Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), speaker’s bureau of Simply Speaking (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
Monday, November 13, 2023
9:00 AM – 11:00 AM PT
Disclosure(s): Other: Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web (Ongoing), Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma (Ongoing), Consultant (Ongoing), received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec (Ongoing), Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), speaker’s bureau of Simply Speaking (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
2522: Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study
Tuesday, November 14, 2023
4:15 PM – 4:25 PM PT
Disclosure(s): Other: Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix, Charlotte’s Web (Ongoing), Atai life sciences, kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma (Ongoing), Consultant (Ongoing), received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc./Philips Elec (Ongoing), Schipher, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), speaker’s bureau of Simply Speaking (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)